So, as we move forward now, obviously, we should see better performance in CAD/CAM in the US. And we’re still cautious around the US equipment market and speaking with our dealers and seeing what’s happening in the marketplace, we’re still cautious. So I think the fact we’ve got our dealer inventory levels where they are, being a bit cautious is how we’ve laid out our guidance for 2023. But keep in mind, we do have some new products that we’ve launched in the space. We are expecting to see growth overall. And so that’s how we’ve laid out 2023. Simon, did you want to add anything?
Simon Campion: I think you covered that well. We had a strong quarter. We’ve got global execution and with our renewed focus on the US, we’re comfortable where we’re at.
Nathan Rich: Great. Thank you.
Operator: Thank you. One moment for our next question please. And it comes from the line of Jeff Johnson with R. W. Baird.
Simon Campion: Good morning.
Operator: All right. We have technical issues with his line. Can I move to the next question, please?
Andrea Daley: Do we have the next question?
Operator: Yes, ma’am. It comes from Erin Wright with Morgan Stanley. Please proceed.
Erin Wright: Great. Thanks for taking the question. So on the restructuring initiative, I think you alluded to SKU count rationalization. Does that have a meaningful impact on sales? And is this something that is embedded in your guidance, both in the near-term and longer-term perspective? And will this be something you’re breaking out for us, how should we be thinking about the timing and magnitude of that. And then just on divestitures, other areas of potential divestitures outside of medical, I understand that you’re kind of limited on what you can say on that front. But also any details you can give us on the margin profile of the Wellspect business, that would be great. Thanks.
Simon Campion: Thank you for the question. So, on the SKUs, we don’t expect to execute any meaningful work on the SKU rationalization in 2023. The organization ran a SKU program a few years ago. And I think, we offset some customers and we offset some of our distribution partners. So we’re going through this in a very thoughtful manner. And so we don’t expect any changes this year, but the plans will be laid out this year, and you should expect to hear some more granularity at the Investor Day in November about that. We provided some color in the prepared remarks about the scale of some of the SKU offerings we have and their contribution to revenue. So hopefully, that provided you some additional color around there. With regard to the divestitures, we obviously considered other parts of our business, too.
But they are more consistent with our thoughts around being a dental developer and manufacturer and commercial team. So while we looked at a number of different opportunities to rationalize our portfolio, the one that we have received several inbounds about and that we’re taking along close look at right now is the Wellspect HealthCare portfolio, and there are no plans to do any further ones at. And then, Glenn?
Erin Wright: Okay.
Glenn Coleman: Yeah, yeah, I would just add just to answer your question on the profitability of the Wellspect business, it is accretive to our overall corporate average. Thanks.
Erin Wright: Okay. Thanks.
Operator: All right. We move along for the next question. Please one moment. And it comes from the line of Jeff Johnson with RW Baird. Please proceed.
